Reuters logo
Grifols signs deal to license Aradigm's Pulmaquin
May 21, 2013 / 6:50 AM / 5 years ago

Grifols signs deal to license Aradigm's Pulmaquin

MADRID, May 21 (Reuters) - Spanish drugmaker Grifols said on Tuesday it has signed an exclusive contract to license U.S. Aradigm Corporation’s Pulmaquin compound and may take a stake in the California-based firm.

Pulmaquin is a dual release ciprofloxacin for inhalation in non-cystic fibrosis bronchiectasis.

In a regulatory filing, Grifols said it will invest up to $65 million to help develop the compound and may spend $25.7 million to buy a 35 percent stake in Aradigm through a capital hike at the U.S. firm, which posted a net loss in the first quarter.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below